[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201909708VA - Methods and antibodies for diabetes-related applications - Google Patents

Methods and antibodies for diabetes-related applications

Info

Publication number
SG11201909708VA
SG11201909708VA SG11201909708VA SG11201909708VA SG 11201909708V A SG11201909708V A SG 11201909708VA SG 11201909708V A SG11201909708V A SG 11201909708VA SG 11201909708V A SG11201909708V A SG 11201909708VA
Authority
SG
Singapore
Prior art keywords
international
massachusetts
antibodies
methods
street
Prior art date
Application number
Inventor
Michael Chorev
Jose A Halperin
Original Assignee
Mellitus Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mellitus Llc filed Critical Mellitus Llc
Publication of SG11201909708VA publication Critical patent/SG11201909708VA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

FigA ELISA of Urine with anti-Amadori mAb y A 0.2703x + QOM Calibration curve \" ay \" Synthetic Peptide Hybrid (rig/ml] Fig. 1B ELISA of Urine with anti-Amadori mAb 1.5 0.75 3 Urine dilution (%) 3.0 2.5 Diabetic with high GCD59 (D2) 2.0 o w' 1 5 D. • 1.0 0.5 0.0 0.18 0.37 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIPO I PCT omit VIII °nolo mu loonmoiflo oimIE (10) International Publication Number WO 2018/195008 Al W O 20 18/ 195 008 Al (51) International Patent Classification: C12N 5/12 (2006.01) C07K 16/28 (2006.01) C12N 15/13 (2006.01) C07C 271/22 (2006.01) CO7K 1/00 (2006.01) G01N 33/53 (2006.01) C07K 1/107 (2006.01) G01N 33/68 (2006.01) (21) International Application Number: PCT/US2018/027856 (22) International Filing Date: 17 April 2018 (17.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/488,346 21 April 2017 (21.04.2017) US (71) Applicant: MELLITUS, LLC [US/US]; CIC Boston, 50 Milk Street, 16th floor, Boston, Massachusetts 02109 (US). (72) Inventors: CHOREV, Michael; 205 South Street, Chest- nut Hill, Massachusetts 02467 (US). HALPERIN, Jose A.; 1433 Beacon Street, Brookline, Massachusetts 02146 (US). (74) Agent: WARD, Donna T. et al.; DT WARD, P.C., 142A MAIN STREET, GROTON, Massachusetts 01450 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) = (54) Title: METHODS AND ANTIBODIES FOR DIABETES-RELATED APPLICATIONS (57) : Anti-CD59 and anti-glycated CD59 antibodies are disclosed. Assays, diagnostics, kits, and assay components including such antibodies are provided. Methods for the assessment of diabetes-related indications are included as well as inhibitors of CD59 glycation and methods of evaluating such inhibitors.
SG11201909708V 2017-04-21 2018-04-17 Methods and antibodies for diabetes-related applications SG11201909708VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762488346P 2017-04-21 2017-04-21
PCT/US2018/027856 WO2018195008A1 (en) 2017-04-21 2018-04-17 Methods and antibodies for diabetes-related applications

Publications (1)

Publication Number Publication Date
SG11201909708VA true SG11201909708VA (en) 2019-11-28

Family

ID=63856388

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201909708V SG11201909708VA (en) 2017-04-21 2018-04-17 Methods and antibodies for diabetes-related applications

Country Status (7)

Country Link
US (1) US11866506B2 (en)
EP (1) EP3612625A4 (en)
JP (2) JP7303182B2 (en)
AU (1) AU2018255244A1 (en)
SG (1) SG11201909708VA (en)
TW (1) TW201902927A (en)
WO (1) WO2018195008A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11866506B2 (en) 2017-04-21 2024-01-09 Mellitus, Llc Anti-CD59 antibodies
CN112924682B (en) * 2019-12-05 2023-02-10 张曼 Application of urine fibrinogen alpha chain protein and polypeptide fragment thereof in normal pregnancy
CN112904009B (en) * 2021-02-19 2022-03-18 山东莱博生物科技有限公司 Magnetic microsphere detection kit for detecting glycosylated CD59 and application thereof
WO2022241236A2 (en) * 2021-05-13 2022-11-17 Mellitus, Llc Methods and reagents for protein analysis
CN115290609B (en) * 2021-12-22 2024-08-09 温州医科大学 Reagent for rapidly detecting heparin and detection method
WO2024166110A1 (en) * 2023-02-12 2024-08-15 Hadasit Medical Research Services And Development Ltd. Targeted reduction of cd59 for use in treating disease

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
FR2619568B1 (en) 1987-08-21 1989-07-07 Centre Nat Rech Scient POLYSTYRENE-DERIVED POLYMERS, PROCESSES FOR THE PREPARATION THEREOF AND APPLICATIONS THEREOF FOR THE ANALYSIS AND PURIFICATION OF ORGANIC MOLECULES
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB9110962D0 (en) 1991-05-21 1991-07-10 Ici Plc Process
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
AU670108B2 (en) 1992-09-11 1996-07-04 Becton Dickinson & Company Improved antibodies to plasmodium falciparum
US5670377A (en) 1996-03-14 1997-09-23 Sansum Medical Research Foundation Method of diagnosing gestational diabetes
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
DK0985039T3 (en) 1997-06-12 2008-06-09 Novartis Int Pharm Ltd Artificial antibody polypeptides
US7439330B2 (en) * 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
US6835545B2 (en) 2000-05-08 2004-12-28 President And Fellows Of Harvard College Methods, products and treatments for diabetes
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
GB0124317D0 (en) * 2001-10-10 2001-11-28 Celltech R&D Ltd Biological products
US7460960B2 (en) 2002-05-10 2008-12-02 Epitome Biosystems, Inc. Proteome epitope tags and methods of use thereof in protein modification analysis
CA2505601C (en) 2002-11-15 2014-10-28 Musc Foundation For Research Development Complement receptor 2 targeted complement modulators
EP1587834B1 (en) 2002-12-23 2011-07-06 Schering Corporation Uses of il-23 mammalian cytokine; related reagents
GB2409456B (en) 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
EP1789449A1 (en) 2004-06-17 2007-05-30 The President and Fellows of Harvard College Anti-glycated cd59 antibodies and uses thereof
CA2568952C (en) 2004-06-18 2019-05-21 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
US7833725B2 (en) 2005-01-06 2010-11-16 President And Fellows Of Harvard College Mass spectrometric methods and products
EP1841455A1 (en) 2005-01-24 2007-10-10 Amgen Inc. Humanized anti-amyloid antibody
US20060246524A1 (en) 2005-04-28 2006-11-02 Christina Bauer Nanoparticle conjugates
WO2007061679A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
WO2007123708A2 (en) 2006-03-31 2007-11-01 Epitome Biosystems, Inc. Post translational modification pattern analysis
WO2007133623A2 (en) 2006-05-10 2007-11-22 Biopeptides Corporation Peptide diagnostic agent for lyme disease
EA200970469A1 (en) 2006-11-09 2010-04-30 АйАрЭм ЭлЭлСи ANTIBODY-AGONISTS OF THE TRKB RECEPTOR AND THEIR APPLICATION
WO2008137165A1 (en) * 2007-05-07 2008-11-13 President And Fellows Of Harvard College Anti-glycated cd59 antibodies and uses thereof
KR20100115340A (en) 2007-10-19 2010-10-27 이무나스 파마 가부시키가이샤 Antibody capable of specifically binding to aβ oligomer, and use thereof
JP5745854B2 (en) 2007-11-13 2015-07-08 テバ バイオファーマシューティカルズ ユーエスエー インコーポレーティッド Humanized antibody against TL1A
EP2575882B1 (en) * 2010-06-02 2017-11-01 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2012027555A2 (en) 2010-08-25 2012-03-01 President And Fellows Of Harvard College Glycated cd59 peptides, their preparation, and uses thereof
AU2012214259B2 (en) 2011-02-10 2017-02-23 President And Fellows Of Harvard College Surrogates of post-translationally modified proteins and uses thereof
EP2543679A1 (en) * 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
WO2013078122A1 (en) 2011-11-22 2013-05-30 President And Fellows Of Harvard College Diabetes diagnosis through the detection of glycated proteins in urine
SG10201704616SA (en) 2012-11-06 2017-07-28 Scholar Rock Inc Compositions and methods for modulating cell signaling
EP3363817A1 (en) * 2012-12-24 2018-08-22 AbbVie Inc. Prolactin receptor binding proteins and uses thereof
EP3620793A1 (en) 2013-12-03 2020-03-11 President And Fellows Of Harvard College Methods and reagents for the assessment of gestational diabetes
US11866506B2 (en) 2017-04-21 2024-01-09 Mellitus, Llc Anti-CD59 antibodies

Also Published As

Publication number Publication date
EP3612625A1 (en) 2020-02-26
JP7303182B2 (en) 2023-07-04
EP3612625A4 (en) 2021-08-18
TW201902927A (en) 2019-01-16
JP2023078133A (en) 2023-06-06
US20210284751A1 (en) 2021-09-16
JP2020517306A (en) 2020-06-18
US11866506B2 (en) 2024-01-09
AU2018255244A1 (en) 2019-10-31
WO2018195008A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
SG11201909708VA (en) Methods and antibodies for diabetes-related applications
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201806150RA (en) Psma and cd3 bispecific t cell engaging antibody constructs
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201407483YA (en) Compositions and methods for modulating smn gene family expression
SG11201408536WA (en) METHOD FOR PRODUCING SOLUBLE FcR AS Fc-FUSION WITH INERT IMMUNOGLOBULIN Fc-REGION AND USES THEREOF
SG11201805449PA (en) Methods of making chimeric antigen receptor -expressing cells
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201906264YA (en) Improved serum albumin binders
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201900772YA (en) Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201809913PA (en) Methods for detecting target nucleic acids in a sample
SG11201805770UA (en) BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
SG11201906341XA (en) Improved serum albumin binders
SG11201808775PA (en) Noninvasive diagnostics by sequencing 5-hydroxymethylated cell-free dna
SG11201805870YA (en) Bispecific t cell engaging antibody constructs
SG11201810003UA (en) Using programmable dna binding proteins to enhance targeted genome modification
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201910096RA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG11201407505XA (en) Aptamer-based multiplexed assays
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201408646VA (en) Dimeric protein with triple mutations
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201908784TA (en) Improved antigen binding receptor formats